To assess the effects of interferon gamma (IFN-gamma) on very primitive hematopoietic progenitor cells, CD34(2+)CD38- human bone marrow cells were isolated and cultured in a two-stage culture system, consisting of a primary liquid culture phase followed by a secondary semisolid colony assay. CD34(2+)CD38- cells needed at least the presence of interleukin 3 (IL-3) and kit ligand (KL) together with either IL-1, IL-6, or granulocyte-colony-stimulating factor (G-CSF) in the primary liquid phase in order to proliferate and differentiate into secondary colony-forming cells (CFC). Addition of IFN-gamma to the primary liquid cultures inhibited cell proliferation and generation of secondary CFC in a dose-dependent way. This was a direct effect since it was also seen in primary single cell cultures of CD34(2+)CD38- cells. The proliferation of more mature CD34+CD38+ cells, however, was not inhibited by IFN-gamma, demonstrating for the first time that IFN-gamma is a specific and direct hematopoietic stem cell inhibitor. IFN-gamma, moreover, preserves the viability of CD34(2+)CD38- cells in the absence of other cytokines. IFN-gamma could, therefore, play a role in the protection of the stem cell compartment from exhaustion in situations of hematopoietic stress and may be useful as stem cell protecting agent against chemotherapy for cancer.
Article|
September 01 1994
Interferon gamma selectively inhibits very primitive CD342+CD38- and not more mature CD34+CD38+ human hematopoietic progenitor cells.
H W Snoeck,
H W Snoeck
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
D R Van Bockstaele,
D R Van Bockstaele
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
G Nys,
G Nys
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
M Lenjou,
M Lenjou
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
F Lardon,
F Lardon
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
L Haenen,
L Haenen
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
I Rodrigus,
I Rodrigus
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
M E Peetermans,
M E Peetermans
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
Z N Berneman
Z N Berneman
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Search for other works by this author on:
H W Snoeck
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
D R Van Bockstaele
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
G Nys
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
M Lenjou
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
F Lardon
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
L Haenen
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
I Rodrigus
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
M E Peetermans
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Z N Berneman
Laboratory of Experimental Hematology, University of Antwerp (UIA) Antwerp University Hospital (UZA), Edegem, Belgium.
Online ISSN: 1540-9538
Print ISSN: 0022-1007
J Exp Med (1994) 180 (3): 1177–1182.
Citation
H W Snoeck, D R Van Bockstaele, G Nys, M Lenjou, F Lardon, L Haenen, I Rodrigus, M E Peetermans, Z N Berneman; Interferon gamma selectively inhibits very primitive CD342+CD38- and not more mature CD34+CD38+ human hematopoietic progenitor cells.. J Exp Med 1 September 1994; 180 (3): 1177–1182. doi: https://doi.org/10.1084/jem.180.3.1177
Download citation file: